Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
06 Octobre 2022 - 07:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, is pleased to announce
Sensorion's participation in two scientific conferences in October
2022.
Laurent Désiré, Ph.D., Sensorion’s Preclinical Development
Director, and Christophe Tran Van Ba, MSC., Preclinical Scientist,
will present in-person a poster entitled “Adeno Associated
Vector-Based Gene Therapy for the Autosomal Recessive Non-Syndromic
Deafness 9 (DFNB9)”, during the poster session on October 13, 2022,
at the European Society of Gene & Cell Therapy (ESGCT)
meeting, taking place in Edinburgh, Scotland, on October 11-14,
2022
Poster: Adeno Associated Vector-Based Gene Therapy for
the Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9) (ID: P202)
Date: Thursday, October 13, 2022 Presenters: Laurent
Désiré, Ph.D., and Christophe Tran Van Ba, MSC. Event:
ESGCT
Valérie Salentey, PharmD, Sensorion’s Regulatory Affairs and
Quality Assurance Director, will make a presentation entitled
“Clarifying the Differences in Orphan Drug Designation Between
the EMA & FDA” and will also take part in a roundtable
entitled “Insight on Case-by-Case Reviews of Various Regulatory
Submissions”, on October 27, 2022 at the Gene Therapy For
Rare Disorders Europe conference, being held in London, UK, on
October 25-27, 2022.
Presentation: Clarifying the differences in Orphan Drug
Designation between the EMA & FDA Date: Thursday,
October 27, 2022 Time: 9.30 am – 10 am BST (10.30 am – 11 am
CEST) Presenter: Valérie Salentey, PharmD Event: Gene
Therapy For Rare Disorders Europe
Roundtable: Insight on Case-by-Case reviews of various
Regulatory Submissions Date: Thursday, October 27, 2022
Time: 10 am – 10.30 am BST (11 am – 11.30 am CEST)
Presenter: Valérie Salentey, PharmD Event: Gene
Therapy For Rare Disorders Europe
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of novel
therapies to restore, treat and prevent hearing loss disorders, a
significant global unmet medical need. Sensorion has built a unique
R&D technology platform to expand its understanding of the
pathophysiology and etiology of inner ear related diseases,
enabling it to select the best targets and mechanisms of action for
drug candidates. Its portfolio combines both small molecule
programs and a preclinical portfolio of inner ear gene therapies.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401
(Arazasetron) progressing in a planned Phase 2 proof of concept
clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
and, with partner Cochlear Limited, in a study of SENS-401 in
patients scheduled for cochlear implantation. Sensorion pursues its
broad strategic collaboration with Institut Pasteur focused on the
genetics of hearing. It has two gene therapy programs aimed at
correcting hereditary monogenic forms of deafness including
OTOF-GT, targeting deafness caused by a mutation of the gene
encoding for otoferlin, and hearing loss related to mutation in
GJB2 gene to potentially address important hearing loss segments in
adults and children (GJB2-GT). The Company is also working on the
identification of biomarkers to improve diagnosis of these
underserved illnesses. www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2021 full year financial report published on April
28, 2022, and available on our website and to the development of
economic conditions, financial markets and the markets in which
Sensorion operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Sensorion to
be materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221005005577/en/
Investor Relations Noemie Djokovic Investor Relations and
Communications +33 6 76 67 98 31
ir.contact@sensorion-pharma.com
International Media Relations Consilium1Strategic
Communications Matthew Cole/Jessica Hodgson +44 7593 572720 +44
7561 424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024